西塔
生物
脱甲基酶
免疫系统
癌症研究
组蛋白
染色质
增强子
主要组织相容性复合体
基因
基因表达
免疫学
遗传学
MHC II级
作者
Daphne Dupéré-Richer,Alberto Riva,Benjamin G. Barwick,Sayantan Maji,Heidi Casellas Román,Jianping Li,Umasankar De,Amin Sobh,Gabrielle Quickstad,Crissandra Piper,Marta Kulis,Teresa Ezponda,José I. Martín‐Subero,Giovanni Tonon,Weizhou Zhang,Constantine S. Mitsiades,Lawrence Boise,Richard L. Bennett,Jonathan D. Licht
出处
期刊:Blood
[Elsevier BV]
日期:2024-07-24
卷期号:144 (14): 1508-1520
被引量:7
标识
DOI:10.1182/blood.2024024518
摘要
The histone H3K27 demethylase KDM6A is a tumor suppressor in multiple cancers, including multiple myeloma (MM). We created isogenic MM cells disrupted for KDM6A and tagged the endogenous protein to facilitate genome wide studies. KDM6A binds genes associated with immune recognition and cytokine signaling. Most importantly, KDM6A binds and activates NLRC5 and CIITA encoding regulators of Major Histocompatibility Complex (MHC) genes. Patient data indicate that NLRC5 and CIITA, are downregulated in MM with low KDM6A expression. Chromatin analysis shows that KDM6A binds poised and active enhancers and KDM6A loss led to decreased H3K27ac at enhancers, increased H3K27me3 levels in body of genes bound by KDM6A and decreased gene expression. Reestablishing histone acetylation with an HDAC3 inhibitor leads to upregulation of MHC expression, offering a strategy to restore immunogenicity of KDM6A deficient tumors. Loss of Kdm6a in murine RAS-transformed fibroblasts led to increased growth in vivo associated with decreased T cell infiltration.
科研通智能强力驱动
Strongly Powered by AbleSci AI